Keyphrases
Cost-effectiveness
100%
Hydroxychloroquine Retinopathy
100%
Netherlands
100%
Disease-associated
100%
Ravulizumab
100%
Chronic Kidney Disease
100%
Standard of Care
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Finerenone
100%
Cardiovascular Events
57%
Kidney Disease Progression
57%
Quality-adjusted Life Years
28%
Flexible Extended Regimen
25%
Societal Perspective
14%
Monotherapy
14%
Parameter Uncertainty
14%
Markov Cohort Model
14%
Time-free
14%
Diabetic Kidney Disease
14%
Chronic Kidney Disease Stage
14%
Kidney Disease Model
14%
Lifetime Cost
14%
Incremental Cost-effectiveness Ratio
14%
Renal Events
14%
Renal Replacement Therapy
14%
Cost Accounts
14%
Incremental Cost
14%
FIDELIO-DKD
14%
Cost-utility
14%
Willingness-to-pay Threshold
14%
Cost to Society
14%
Medical Costs
14%
Disease Pathways
14%
Patient Care
14%
Type 2 Diabetic Patients
14%
Model Robustness
14%
Utility Costs
14%
Treatment Options
14%
Risk Reduction
14%
Dutch
14%
Parameter Influence
14%
Neovascular AMD
12%
Net Price
12%
ALSYMPCA
11%
Pharmacology, Toxicology and Pharmaceutical Science
Retinopathy
100%
Hydroxychloroquine
100%
Ravulizumab
100%
Lutetium 177
100%
Castration Resistant Prostate Cancer
100%
Finerenone
100%
Chronic Kidney Failure
100%
Non Insulin Dependent Diabetes Mellitus
100%
Eculizumab
100%
Paroxysmal Nocturnal Hemoglobinuria
100%
Radiopharmaceutical Agent
44%
Faricimab
27%
Disease Exacerbation
22%
Autoimmune Disease
20%
Visual Impairment
20%
Disease Activity
14%
Symptom
14%
Disease Model
11%
Clinical Trial
11%
Disease
11%
Overall Survival
11%
Monotherapy
11%
Replacement Therapy
11%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Eculizumab
100%
Ravulizumab
100%
Health Care Cost
100%
Paroxysmal Nocturnal Hemoglobinuria
100%
Quality Adjusted Life Year
50%
Quality of Life
25%
Infusion
12%
Lifespan
12%
Disease Activity
12%
Symptom
12%